The Med Tech Sentinel covers the latest in medical technology innovation and investment opportunity, with emphasis on emerging companies. It is the first blog located at OneMedPlace, a virtual community of entrepreneurs, investors, physicians, and other constituents of the healthcare and life sciences fields. OneMedPlace is the creation of its namesake, a New York-based communications firm dedicated to bringing efficiency to the chaos of company development.
This week's video profile covers ScyFix. ScyFix has spent eight years developing the first micro-current neuromodulation (MCN) device to treat degenerative eye diseases such as macular degeneration. http://www.onemedplace.com/
About ScyFix:
ScyFix iScyFIX is developing sight-saving technologies for people suffering from degenerative eye diseases for which there are currently no cures or therapies. ScyFIX offers the only patented micro-current stimulation device for the treatment of macular degeneration, Stargardt's disease, retinitis pigmentosa and other degenerative eye diseases. ScyFix, please visit http://www.onemedplace.com/
About OneMedPlace: OneMedPlace http://www.onemedplace.com is a virtual community of health care and life science companies. It has, for the first time, put in place the innovations that will shape the future of health and medicine—emerging companies and technologies seeking capital, distribution, visibility and resources to help finance, build and grow, and investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.
